A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma

[1]  P. Catalano,et al.  Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group's Study E3200. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Jeffrey E. Lee,et al.  Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[4]  F. Kabbinavar,et al.  Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer , 2005, Oncology.

[5]  D. Cunningham,et al.  Managing Patients Treated with Bevacizumab Combination Therapy , 2005, Oncology.

[6]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[7]  J. Tao,et al.  Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach , 2005, The British journal of dermatology.

[8]  J. Berlin,et al.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab , 2005, Journal of surgical oncology.

[9]  F. Kabbinavar,et al.  Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Kirkwood,et al.  Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.

[13]  J. Mestan,et al.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.

[14]  M. Dewhirst,et al.  Circulating D‐dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma , 2004, Cancer.

[15]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Coppola,et al.  Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor , 2004, Cancer Research.

[17]  James S Goydos,et al.  Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. , 2003, Journal of the American College of Surgeons.

[18]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[19]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[20]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Becker,et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.

[22]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[23]  D. Hicklin,et al.  Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis , 2002, The Journal of experimental medicine.

[24]  P. Gaulard,et al.  Impact of high-dose chemotherapy on peripheral T-cell lymphomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Akslen,et al.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. , 2001, The American journal of pathology.

[26]  N. Cascinelli,et al.  The New Melanoma Staging System , 2001, Tumori.

[27]  S. Ugurel,et al.  Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Lacal,et al.  Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. , 2000, The Journal of investigative dermatology.

[29]  E. Rofstad,et al.  Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. , 2000, Cancer research.

[30]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[31]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[32]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[33]  C. Begg,et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Grandér,et al.  Molecular mechanisms underlying interferon-α-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins , 1999, Oncogene.

[35]  R G Blasberg,et al.  Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. , 1998, Cancer research.

[36]  C. Bucana,et al.  Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. , 1998, Cancer research.

[37]  P. Heikkilä,et al.  Enhanced expression of vascular endothelial growth factor in metastatic melanoma. , 1997, British Journal of Cancer.

[38]  Jordi Graells,et al.  Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase , 1997, Journal of cutaneous pathology.

[39]  D. Hanahan,et al.  Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Mannucci,et al.  Hypercoagulability and hyperfibrinolysis in patients with melanoma. , 1996, Thrombosis research.

[41]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[42]  J. Mulliken,et al.  Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy , 1992, The New England journal of medicine.

[43]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.